Clinical trial
Post Marketing Surveillance on Safety Evaluation of REVLIMID® (Lenalidomide) Treatment of Myelodysplastic Syndromes Associated With a Deletion 5q or Mantle Cell Lymphoma in Korea
NCT04036448 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Post Marketing Surveillance on Safety Evaluation of REVLIMID® (Lenalidomide) Treatment of Myelodysplastic Syndromes Associated With a Deletion 5q or Mantle Cell Lymphoma in Korea
- Lead sponsor
- Celgene
- Phase
- Observational
- Overall status
- Completed
- Start date
- November 28, 2019
- Completion date
- August 15, 2023
- Enrollment
- 28 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.